A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes

NCT07122102 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Cofrogliptin
DRUG: Acarbose

Sponsor

Haisco Pharmaceutical Group Co., Ltd.